{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T05:20:26Z","timestamp":1777872026445,"version":"3.51.4"},"reference-count":100,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Mol Med"],"DOI":"10.3892\/ijmm.2020.4596","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T12:06:26Z","timestamp":1588766786000},"page":"3-16","source":"Crossref","is-referenced-by-count":238,"title":["Towards effective COVID\u201119 vaccines: Updates, perspectives and challenges (Review)"],"prefix":"10.3892","volume":"46","author":[{"given":"Daniela","family":"Calina","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anca","family":"Docea","sequence":"additional","affiliation":[{"name":"Department of Toxicology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Demetrios","family":"Petrakis","sequence":"additional","affiliation":[{"name":"Department of Forensic Sciences and Toxicology, Faculty of Medicine, University of Crete, 71003 Heraklion, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Egorov","sequence":"additional","affiliation":[{"name":"FSBSI \u2018Chumakov Federal Scientific Center for Research and Development of Immune\u2011 and Biological Products of Russian Academy of Sciences\u2019, 108819 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aydar","family":"Ishmukhametov","sequence":"additional","affiliation":[{"name":"FSBSI \u2018Chumakov Federal Scientific Center for Research and Development of Immune\u2011 and Biological Products of Russian Academy of Sciences\u2019, 108819 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexsandr","family":"Gabibov","sequence":"additional","affiliation":[{"name":"Russian Academy of Sciences, 119991 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Shtilman","sequence":"additional","affiliation":[{"name":"D.I. Mendeleyev University of Chemical Technology, 125047 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Kostoff","sequence":"additional","affiliation":[{"name":"School of Public Policy, Georgia Institute of Technology, Gainesville, VA 20155, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F\u00e9lix","family":"Carvalho","sequence":"additional","affiliation":[{"name":"UCIBIO, REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050\u2011313 Porto, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Vinceti","sequence":"additional","affiliation":[{"name":"Section of Public Health, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, I-41125 Modena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Demetrios","family":"Spandidos","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Virology, Medical School, University of Crete, 71409 Heraklion, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aristidis","family":"Tsatsakis","sequence":"additional","affiliation":[{"name":"Department of Forensic Sciences and Toxicology, Faculty of Medicine, University of Crete, 71003 Heraklion, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2020,5,6]]},"reference":[{"key":"key20200713162653_b1-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13578-020-00404-4","article-title":"SARS-CoV-2 and COVID-19: The most important research questions","volume":"10","author":"Yuen","year":"2020","journal-title":"Cell Biosci"},{"key":"key20200713162653_b2-ijmm-46-01-0003","unstructured":"KostoffRNCombining Tactical and Strategic Treatments for COVID-19Georgia Institute of Technology2020http:\/\/hdl.handle.net\/1853\/62523 Accessed March 23 2020"},{"key":"key20200713162653_b3-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"126473","DOI":"10.1016\/j.jtemb.2020.126473","article-title":"The long-term oral exposure to titanium dioxide impaired immune functions and triggered cytotoxic and genotoxic impacts in rats","volume":"60","author":"Hashem","year":"2020","journal-title":"J Trace Elem Med Biol"},{"key":"key20200713162653_b4-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1136\/thoraxjnl-2018-212529","article-title":"Urban airborne particle exposure impairs human lung and blood Mycobacterium tuberculosis immunity","volume":"74","author":"Torres","year":"2019","journal-title":"Thorax"},{"key":"key20200713162653_b5-ijmm-46-01-0003","first-page":"20","article-title":"COVID-19 in Northern Italy: An integrative overview of factors possibly influencing the sharp increase of the outbreak (Review)","volume":"22","author":"Goumenou","year":"2020","journal-title":"Mol Med Rep"},{"key":"key20200713162653_b6-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1080\/08923973.2018.1533967","article-title":"Hematological and immunological impairment following in-utero and postnatal exposure to aluminum sulfate in female offspring of albino rats","volume":"41","author":"Omran","year":"2019","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"key20200713162653_b7-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/pai.13099","article-title":"Adverse health outcomes associated with fetal alcohol exposure: A systematic review focused on immune-related outcomes","volume":"30","author":"Reid","year":"2019","journal-title":"Pediatr Allergy Immunol"},{"key":"key20200713162653_b8-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12989-017-0199-z","article-title":"Mechanistic understanding of nanoparticles' interactions with extracellular matrix: The cell and immune system","volume":"14","author":"Engin","year":"2017","journal-title":"Part Fibre Toxicol"},{"key":"key20200713162653_b9-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/tox.21936","article-title":"In vivo short-term exposure to residual oil fly ash impairs pulmonary innate immune response against environmental mycobacterium infection","volume":"30","author":"Delfosse","year":"2015","journal-title":"Environ Toxicol"},{"key":"key20200713162653_b10-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.toxlet.2019.09.004","article-title":"Genotoxic, cytotoxic, and cytopathological effects in rats exposed for 18 months to a mixture of 13 chemicals in doses below NOAEL levels","volume":"316","author":"Tsatsakis","year":"2019","journal-title":"Toxicol Lett"},{"key":"key20200713162653_b11-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.1016\/j.toxlet.2016.06.1666","article-title":"Study design for the determination of toxicity from long-term-low-dose exposure to complex mixtures of pesticides, food additives and lifestyle products","volume":"258","author":"Docea","year":"2016","journal-title":"Toxicol Lett"},{"key":"key20200713162653_b12-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.fct.2018.03.052","article-title":"Six months exposure to a real life mixture of 13 chemicals' below individual NOAELs induced non monotonic sex-dependent biochemical and redox status changes in rats","volume":"115","author":"Docea","year":"2018","journal-title":"Food Chem Toxicol"},{"key":"key20200713162653_b13-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.toxlet.2019.04.005","article-title":"Adverse and hormetic effects in rats exposed for 12 months to low dose mixture of 13 chemicals: RLRS part III","volume":"310","author":"Docea","year":"2019","journal-title":"Toxicol Lett"},{"key":"key20200713162653_b14-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.toxlet.2019.09.015","article-title":"A mixture of routinely encountered xenobiotics induces both redox adaptations and perturbations in blood and tissues of rats after a long-term low-dose exposure regimen: The time and dose issue","volume":"317","author":"Fountoucidou","year":"2019","journal-title":"Toxicol Lett"},{"key":"key20200713162653_b15-ijmm-46-01-0003","article-title":"COVID-19, an opportunity to reevaluate the correlation between long-term effects of anthropogenic pollutants on viral epidemic\/pandemic events and prevalence","author":"Tsatsakis","journal-title":"Food Chem Toxicol"},{"key":"key20200713162653_b16-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"46","DOI":"10.7774\/cevr.2015.4.1.46","article-title":"Clinical vaccine development","volume":"4","author":"Han","year":"2015","journal-title":"Clin Exp Vaccine Res"},{"key":"key20200713162653_b17-ijmm-46-01-0003","first-page":"877","article-title":"Double therapy with pegylated Interferon and Ribavirin for chronic hepatitis C. A pharmacogenenetic guide for predicting adverse events","volume":"65","author":"Kamal","year":"2017","journal-title":"Farmacia"},{"key":"key20200713162653_b18-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1586\/14760584.2015.1091733","article-title":"The costs and effectiveness of large Phase III pre-licensure vaccine clinical trials","volume":"14","author":"Black","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"key20200713162653_b19-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"M563","DOI":"10.1093\/gerona\/57.9.M563","article-title":"Effect of a complete nutritional supplement on antibody response to influenza vaccine in elderly people","volume":"57","author":"Wouters-Wesseling","year":"2002","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"key20200713162653_b20-ijmm-46-01-0003","first-page":"218","article-title":"Association of nutraceutical supplements with longer telomere length","volume":"44","author":"Tsoukalas","year":"2019","journal-title":"Int J Mol Med"},{"key":"key20200713162653_b21-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12948-017-0077-0","article-title":"Immunosenescence in aging: Between immune cells depletion and cytokines up-regulation","volume":"15","author":"Ventura","year":"2017","journal-title":"Clin Mol Allergy"},{"key":"key20200713162653_b22-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"2154S","DOI":"10.3945\/jn.109.105312","article-title":"Landscape analysis of interactions between nutrition and vaccine responses in children","volume":"139","author":"Savy","year":"2009","journal-title":"J Nutr"},{"key":"key20200713162653_b23-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"181","DOI":"10.5152\/tpa.2014.2206","article-title":"Vaccination in patients with immunosuppression","volume":"49","author":"Arvas","year":"2014","journal-title":"Turk Pediatri Ars"},{"key":"key20200713162653_b24-ijmm-46-01-0003","article-title":"Red Book: 2012 Report of the Committee on Infectious Diseases","author":"Pickering"},{"issue":"Suppl 6","key":"key20200713162653_b25-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"S486","DOI":"10.1093\/clinids\/13.Supplement_6.S486","article-title":"Nutritional effects on response of children in developing countries to respiratory tract pathogens: Implications for vaccine development","volume":"13","author":"Keusch","year":"1991","journal-title":"Rev Infect Dis"},{"issue":"Suppl 7","key":"key20200713162653_b26-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"S504","DOI":"10.1086\/432007","article-title":"The immunopathogenesis of sepsis in elderly patients","volume":"41","author":"Opal","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key20200713162653_b27-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/08916930600597326","article-title":"Reduced tetanus antibody titers in overweight children","volume":"39","author":"Eliakim","year":"2006","journal-title":"Autoimmunity"},{"key":"key20200713162653_b28-ijmm-46-01-0003","first-page":"946","article-title":"Etiological diagnosis and pharmacotherapeutic management of parap-neumonic pleurisy","volume":"64","author":"Calina","year":"2016","journal-title":"Farmacia"},{"key":"key20200713162653_b29-ijmm-46-01-0003","first-page":"17","article-title":"Zinc and respiratory tract infections: Perspectives for COVID-19 (Review)","volume":"46","author":"Skalny","year":"2020","journal-title":"Int J Mol Med"},{"key":"key20200713162653_b30-ijmm-46-01-0003","first-page":"151","article-title":"Vaccines of the future","volume-title":"Understanding Modern Vaccines: perspectives in Vaccinology","author":"Stanberry","year":"2011"},{"key":"key20200713162653_b31-ijmm-46-01-0003","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1017\/S0098858800009424","article-title":"Orphan drugs: The question of products liability","volume":"10","author":"Scharf","year":"1985","journal-title":"Am J Law Med"},{"key":"key20200713162653_b32-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1017\/S0266462300002348","article-title":"Evaluation of orphan products by the U.S. Food and Drug Administration","volume":"8","author":"Haffner","year":"1992","journal-title":"Int J Technol Assess Health Care"},{"key":"key20200713162653_b33-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1046\/j.1365-3156.1997.d01-234.x","article-title":"Will the fight against tropical diseases benefit from orphan drug status?","volume":"2","author":"Olliario","year":"1997","journal-title":"Trop Med Int Health"},{"key":"key20200713162653_b34-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S0264-410X(98)00246-1","article-title":"The introduction of new vaccines into developing countries","volume":"17","author":"Mahoney","year":"1999","journal-title":"Vaccine"},{"key":"key20200713162653_b35-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/S0264-410X(97)00053-4","article-title":"A systematic method for evaluating the potential viability of local vaccine producers","volume":"15","author":"Milstien","year":"1997","journal-title":"Vaccine"},{"key":"key20200713162653_b36-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"982","DOI":"10.3389\/fimmu.2017.00982","article-title":"Immunobiography and the heterogeneity of immune responses in the elderly: A focus on inflamation and trained immunity","volume":"8","author":"Franceschi","year":"2017","journal-title":"Front Immunol"},{"key":"key20200713162653_b37-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1093\/cid\/ciz135","article-title":"Principal controversies in vaccine safety in the United States","volume":"69","author":"DeStefano","year":"2019","journal-title":"Clin Infect Dis"},{"key":"key20200713162653_b38-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"e57755","DOI":"10.1371\/journal.pone.0057755","article-title":"Risk in vaccine research and development quantified","volume":"8","author":"Pronker","year":"2013","journal-title":"PLoS One"},{"key":"key20200713162653_b39-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/nbt0910-910","article-title":"First-in-human clinical trials with vaccines - what regulators want","volume":"28","author":"Goetz","year":"2010","journal-title":"Nat Biotechnol"},{"key":"key20200713162653_b40-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1080\/21645515.2019.1586040","article-title":"Safety profile of the RTS, S\/AS01 malaria vaccine in infants and children: Additional data from a phase III randomized controlled trial in sub-Saharan Africa","volume":"15","author":"Guerra Mendoza","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"key20200713162653_b41-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"8218","DOI":"10.1073\/pnas.2005456117","article-title":"News feature: Avoiding pitfalls in the pursuit of a COVID-19 vaccine","volume":"117","author":"Peeples","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20200713162653_b42-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.4161\/rna.22269","article-title":"Developing mRNA-vaccine technologies","volume":"9","author":"Schlake","year":"2012","journal-title":"RNA Biol"},{"key":"key20200713162653_b43-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.7150\/ijbs.45134","article-title":"COVID-19: What has been learned and to be learned about the novel coronavirus disease","volume":"16","author":"Yi","year":"2020","journal-title":"Int J Biol Sci"},{"key":"key20200713162653_b44-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"127","DOI":"10.4103\/0974-777X.170495","article-title":"The Ebola Outbreak of 2014-2015: From Coordinated Multilateral Action to Effective Disease Containment, Vaccine Development, and Beyond","volume":"7","author":"Wojda","year":"2015","journal-title":"J Glob Infect Dis"},{"key":"key20200713162653_b45-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1080\/21645515.2017.1356495","article-title":"Vaccine development and trials in low and lower-middle income countries: Key issues, advances and future opportunities","volume":"13","author":"Grenham","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"key20200713162653_b46-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/S1473-3099(18)30292-5","article-title":"Respiratory Syncytial Virus Network (ReSViNET) Foundation: The respiratory syncytial virus vaccine landscape: Lessons from the graveyard and promising candidates","volume":"18","author":"Mazur","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"key20200713162653_b47-ijmm-46-01-0003","first-page":"1631","article-title":"A new threat from an old enemy: Re-emergence of coronavirus (Review)","volume":"45","author":"Docea","year":"2020","journal-title":"Int J Mol Med"},{"key":"key20200713162653_b48-ijmm-46-01-0003","first-page":"2293","article-title":"[Editorial] Possibility of transmission through dogs being a contributing factor to the extreme Covid-19 outbreak in North Italy","volume":"21","author":"Goumenou","year":"2020","journal-title":"Mol Med Rep"},{"key":"key20200713162653_b49-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/jmv.25681","article-title":"Emerging coronaviruses: Genome structure, replication, and pathogenesis","volume":"92","author":"Chen","year":"2020","journal-title":"J Med Virol"},{"key":"key20200713162653_b50-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41423-020-0407-x","article-title":"COVID-19: A new challenge for human beings","volume":"17","author":"Yang","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"key20200713162653_b51-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"key20200713162653_b52-ijmm-46-01-0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.05.034","article-title":"Structural and functional basis of SARS-CoV-2 entry by using human ACE2","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"key20200713162653_b53-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"104833","DOI":"10.1016\/j.phrs.2020.104833","article-title":"Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor","volume":"157","author":"Li","year":"2020","journal-title":"Pharmacol Res"},{"key":"key20200713162653_b54-ijmm-46-01-0003","doi-asserted-by":"crossref","first-page":"e105114","DOI":"10.15252\/embj.2020105114","article-title":"SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells","volume":"4","author":"Lukassen","year":"2020","journal-title":"EMBO J"},{"key":"key20200713162653_b55-ijmm-46-01-0003","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00688-2020","article-title":"ACE-2 expression in the small airway epithelia of smokers and COPD patients: Implications for COVID-19","author":"Leung","year":"2020","journal-title":"Eur Respir J"},{"key":"key20200713162653_b56-ijmm-46-01-0003","article-title":"Genotype and phenotype of COVID-19: Their roles in pathogenesis","author":"Mousavizadeh","year":"2020","journal-title":"J Microbiol Immunol"},{"key":"key20200713162653_b57-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.3390\/v2081803","article-title":"Coronavirus genomics and bioinformatics analysis","volume":"2","author":"Woo","year":"2010","journal-title":"Viruses"},{"key":"key20200713162653_b58-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1086\/500469","article-title":"Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome","volume":"193","author":"Liu","year":"2006","journal-title":"J Infect Dis"},{"key":"key20200713162653_b59-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"102437","DOI":"10.1016\/j.bcmd.2020.102437","article-title":"Increased expression of CD8 marker on T-cells in COVID-19 patients","volume":"83","author":"Ganji","year":"2020","journal-title":"Blood Cells Mol Dis"},{"key":"key20200713162653_b60-ijmm-46-01-0003","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxrep.2020.04.012","article-title":"Editorial: Nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system","author":"Farsalinos","year":"2020","journal-title":"Toxicol Rep"},{"key":"key20200713162653_b61-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.7150\/ijbs.45123","article-title":"Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2","volume":"16","author":"Zhou","year":"2020","journal-title":"Int J Biol Sci"},{"key":"key20200713162653_b62-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000503030","article-title":"Innate immune evasion by human respiratory RNA viruses","volume":"12","author":"Kikkert","year":"2020","journal-title":"J Innate Immun"},{"key":"key20200713162653_b63-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41541-020-0159-8","article-title":"The promise of mRNA vaccines: A biotech and industrial perspective","volume":"5","author":"Jackson","year":"2020","journal-title":"NPJ Vaccines"},{"key":"key20200713162653_b64-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3389\/fimmu.2019.00594","article-title":"Advances in mRNA Vaccines for infectious diseases","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Immunol"},{"key":"key20200713162653_b65-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"key20200713162653_b66-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ymthe.2019.01.020","article-title":"mRNA as a transformative technology for vaccine development to control infectious diseases","volume":"27","author":"Maruggi","year":"2019","journal-title":"Mol Ther"},{"key":"key20200713162653_b67-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/wrna.1189","article-title":"Messenger RNA-based vaccines: Progress challenges, applications","volume":"4","author":"Kramps","year":"2013","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"key20200713162653_b68-ijmm-46-01-0003","unstructured":"World Health Organization (WHO)DRAFT landscape of COVID-19 candidate vaccinesWHOGeneva2020https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1. Accessed April 11 2020"},{"key":"key20200713162653_b69-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1586\/14760584.2016.1124762","article-title":"Molecular mechanisms for enhanced DNA vaccine immunogenicity","volume":"15","author":"Li","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"key20200713162653_b70-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"E3605","DOI":"10.3390\/ijms19113605","article-title":"DNA Vaccines-How Far From Clinical Use?","volume":"19","author":"Hobernik","year":"2018","journal-title":"Int J Mol Sci"},{"key":"key20200713162653_b71-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1093\/cid\/cir334","article-title":"Clinical applications of DNA vaccines: Current progress","volume":"53","author":"Ferraro","year":"2011","journal-title":"Clin Infect Dis"},{"key":"key20200713162653_b72-ijmm-46-01-0003","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-020-00073-5","article-title":"The COVID-19 vaccine development landscape","author":"Thanh Le","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"key20200713162653_b73-ijmm-46-01-0003","unstructured":"US National Library of Medicine, ClinicalTrials.govA Study of a Candidate COVID-19 Vaccine (COV001)https:\/\/clinical-trials.gov\/ct2\/show\/NCT04324606. Accessed March 27 2020"},{"key":"key20200713162653_b74-ijmm-46-01-0003","unstructured":"Clinical Trials ArenaUniversity of Oxford starts enrolment for Covid-19 vaccine trialhttps:\/\/www.clinicaltrialsarena.com\/news\/oxford-university-covid-19-vaccine-trial\/ Accessed March 30, 2020"},{"key":"key20200713162653_b75-ijmm-46-01-0003","unstructured":"Clinical Trials ArenaInovio commences Phase I trial of DNA vaccine for Covid-19https:\/\/www.clinicaltrialsarena.com\/news\/inovio-SARS-COV-2-vaccine-trial\/. Accessed April 7, 2020"},{"key":"key20200713162653_b76-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.virusres.2014.11.013","article-title":"Receptor-binding domain-based subunit vaccines against MERS-CoV","volume":"202","author":"Zhang","year":"2015","journal-title":"Virus Res"},{"key":"key20200713162653_b77-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"18","DOI":"10.7774\/cevr.2012.1.1.18","article-title":"A review of vaccine development and research for industry animals in Korea","volume":"1","author":"Lee","year":"2012","journal-title":"Clin Exp Vaccine Res"},{"key":"key20200713162653_b78-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/21655979.2016.1191707","article-title":"Recent advances in the production of recombinant subunit vaccines in Pichia pastoris","volume":"7","author":"Wang","year":"2016","journal-title":"Bioengineered"},{"key":"key20200713162653_b79-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"97","DOI":"10.7774\/cevr.2013.2.2.97","article-title":"Viral vectors for vaccine applications","volume":"2","author":"Choi","year":"2013","journal-title":"Clin Exp Vaccine Res"},{"key":"key20200713162653_b80-ijmm-46-01-0003","first-page":"327","article-title":"Virus like particles - A recent advancement in vaccine development","volume":"55","author":"Sarkar","year":"2019","journal-title":"Korean J Microbiol"},{"key":"key20200713162653_b81-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41541-017-0006-8","article-title":"Escherichia coli-derived virus-like particles in vaccine development","volume":"2","author":"Huang","year":"2017","journal-title":"NPJ Vaccines"},{"key":"key20200713162653_b82-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3390\/vaccines3020373","article-title":"Influenza vaccination strategies: Comparing inactivated and live attenuated influenza vaccines","volume":"3","author":"Sridhar","year":"2015","journal-title":"Vaccines (Basel)"},{"key":"key20200713162653_b83-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nbt.1635","article-title":"Rationalizing the development of live attenuated virus vaccines","volume":"28","author":"Lauring","year":"2010","journal-title":"Nat Biotechnol"},{"key":"key20200713162653_b84-ijmm-46-01-0003","unstructured":"US National Library of Medicine, ClinicalTrials.govImmunity and Safety of Covid-19 Synthetic Minigene Vaccinehttps:\/\/clini-caltrials.gov\/ct2\/show\/NCT04276896. Accessed February 19, 2020"},{"key":"key20200713162653_b85-ijmm-46-01-0003","unstructured":"US National Library of Medicine, ClinicalTrials.govSafety and Immunity of Covid-19 aAPC Vaccinehttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT04299724. Accessed March 9, 2020"},{"key":"key20200713162653_b86-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"6535","DOI":"10.1038\/sj.onc.1207877","article-title":"Polio vaccines, Simian Virus 40, and human cancer: The epidemiologic evidence for a causal association","volume":"23","author":"Dang-Tan","year":"2004","journal-title":"Oncogene"},{"key":"key20200713162653_b87-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1001\/jama.279.4.292","article-title":"Contamination of poliovirus vaccines with simian virus 40 (1955-1963) and subsequent cancer rates","volume":"279","author":"Strickler","year":"1998","journal-title":"JAMA"},{"key":"key20200713162653_b88-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.vaccine.2010.11.028","article-title":"Analysis of porcine circovirus type 1 detected in Rotarix vaccine","volume":"29","author":"Baylis","year":"2011","journal-title":"Vaccine"},{"key":"key20200713162653_b89-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.3389\/fmicb.2018.02991","article-title":"Viral-induced enhanced disease illness","volume":"9","author":"Smatti","year":"2018","journal-title":"Front Microbiol"},{"key":"key20200713162653_b90-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.micinf.2020.02.006","article-title":"Is COVID-19 receiving ADE from other coronaviruses?","volume":"22","author":"Tetro","year":"2020","journal-title":"Microbes Infect"},{"key":"key20200713162653_b91-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1080\/22221751.2019.1624482","article-title":"Antibodies and vaccines against Middle East respiratory syndrome coronavirus","volume":"8","author":"Xu","year":"2019","journal-title":"Emerg Microbes Infect"},{"key":"key20200713162653_b92-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1177\/003335490712200215","article-title":"Immunity for the people: The challenge of achieving high vaccine coverage in American history","volume":"122","author":"Colgrove","year":"2007","journal-title":"Public Health Rep"},{"key":"key20200713162653_b93-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.4161\/hv.24696","article-title":"The effect of ageing of the immune system on vaccination responses","volume":"9","author":"Lord","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"key20200713162653_b94-ijmm-46-01-0003","first-page":"637","article-title":"Human papilloma virus: Apprehending the link with carcinogenesis and unveiling new research avenues (Review)","volume":"52","author":"Boda","year":"2018","journal-title":"Int J Oncol"},{"key":"key20200713162653_b95-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/21645515.2015.1093263","article-title":"Primary vaccine failure to routine vaccines: Why and what to do?","volume":"12","author":"Wiedermann","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"key20200713162653_b96-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S0264-410X(99)00271-6","article-title":"DNA and RNA-based vaccines: Principles, progress and prospects","volume":"18","author":"Leitner","year":"1999","journal-title":"Vaccine"},{"key":"key20200713162653_b97-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","article-title":"Coronaviruses: An overview of their replication and pathogenesis","volume":"1282","author":"Fehr","year":"2015","journal-title":"Methods Mol Biol"},{"key":"key20200713162653_b98-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/nrmicro2147","article-title":"Coronaviruses post-SARS: Update on replication and pathogenesis","volume":"7","author":"Perlman","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"key20200713162653_b99-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4103\/0975-7406.124301","article-title":"Use of rodents as models of human diseases","volume":"6","author":"Vandamme","year":"2014","journal-title":"J Pharm Bioallied Sci"},{"key":"key20200713162653_b100-ijmm-46-01-0003","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.conctc.2018.08.001","article-title":"Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review","volume":"11","author":"Fogel","year":"2018","journal-title":"Contemp Clin Trials Commun"}],"container-title":["International Journal of Molecular Medicine"],"original-title":[],"deposited":{"date-parts":[[2021,3,13]],"date-time":"2021-03-13T03:48:03Z","timestamp":1615607283000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ijmm.2020.4596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,6]]},"references-count":100,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,5,6]]}},"URL":"https:\/\/doi.org\/10.3892\/ijmm.2020.4596","relation":{},"ISSN":["1107-3756","1791-244X"],"issn-type":[{"value":"1107-3756","type":"print"},{"value":"1791-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,6]]}}}